# Liver Cancer (HCC)
Hepatocellular carcinoma is the most common primary liver cancer and one of the leading causes of cancer-related mortality worldwide.
Most HCC develops on a background of chronic liver disease, including hepatitis B, hepatitis C, alcoholic liver disease, and metabolic liver injury.
Those underlying states share several biological themes.
They include chronic inflammation, oxidative stress, hepatocyte damage, and progressive fibrosis.
Urolithin A has preclinical activity across all of those areas.
The HCC evidence falls into two connected streams.
The first is direct anticancer activity in liver-cancer cell lines.
The second is hepatoprotective and gut-liver-axis activity that may matter upstream, before or alongside malignant transformation.
Both are relevant here.
All evidence reviewed on this page is preclinical.
No clinical trials of Urolithin A in HCC patients have been identified as of April 2026.
### Why the liver is a relevant target
Several features make the liver a biologically logical site for Urolithin A activity.
* after colonic absorption, Urolithin A reaches the liver through portal circulation before wider systemic distribution
* chronic oxidative stress and NF-κB-driven inflammation are major drivers of HCC biology and major Urolithin A targets
* Wnt/β-catenin signalling, another recurrent Urolithin A target, is aberrantly activated in a meaningful subset of HCCs
* the gut-liver axis matters directly in chronic liver disease and HCC risk
This combination makes liver cancer one of the more conceptually coherent settings for the compound, even though the direct in vivo HCC dataset is still less developed than in pancreatic or colorectal cancer.
### Direct anticancer activity in HCC cell lines
#### HepG2 antiproliferative and antioxidant effects
HepG2 is the most commonly used HCC cell line in the Urolithin A literature.
In HepG2 cells, Urolithin A showed dose-dependent antiproliferative activity.
Reported effects included:
* lower intracellular reactive oxygen species
* higher superoxide dismutase activity
* higher glutathione peroxidase activity
* reduced cell proliferation at higher concentrations
This is an interesting pattern because the compound appears both cytostatic and able to change the oxidative environment of liver-cancer cells.
Given how central oxidative stress is to hepatocarcinogenesis, that dual effect matters.
#### β-catenin and TCF pathway suppression
In HCC cell systems, Urolithin A has also reduced viability through suppression of Wnt/β-catenin/TCF signalling.
Reported effects include:
* lower β-catenin expression
* reduced TCF/LEF transcriptional activation
* lower c-MYC expression
* lower cyclin D1 expression
* higher p53 and p38-MAPK signalling
* caspase-3 activation and apoptosis
This pattern is mechanistically coherent and fits with what is seen in other Wnt-relevant cancers such as colorectal cancer.
### HBV-associated HCC — Lin28a and let-7a axis
This is one of the most distinctive HCC findings in the Urolithin A literature.
HBV-associated HCC matters clinically because it remains a major global subtype, especially in Asia and sub-Saharan Africa.
In HepG2.2.15 cells, which model HBV-positive HCC, Urolithin A appeared to restore the Lin28a/let-7a axis.
That matters because HBV, through HBx-related biology, can drive Lin28a expression and suppress let-7a microRNA, allowing oncogenic targets such as HMGA2 and K-RAS to accumulate.
After Urolithin A treatment, reported effects included:
* lower Sp-1, Lin28a, and Zcchc11 expression
* higher let-7a expression
* lower HMGA2 and K-RAS expression downstream
* reduced invasion
* caspase-3 cleavage and apoptosis
* a lower Bcl-2/Bax ratio
This gives Urolithin A a more subtype-specific mechanistic foothold in HBV-associated liver cancer than many natural compounds have.
The finding is still in vitro.
It is nevertheless unusually specific.
### Sirt1 and FOXO1 axis in HCC
As in glioblastoma, Urolithin A also appears to activate Sirt1 and FOXO1 signalling in HCC cells.
That is important because it suggests the Sirt1-FOXO1 mechanism is not confined to one cancer type.
Instead, it may represent a broader recurring axis through which Urolithin A can promote cell-cycle arrest and apoptosis.
Cross-cancer mechanistic consistency like this adds credibility to the biology.
### Nrf2 pathway — the hepatoprotective dimension
The Nrf2 story is especially important in liver disease.
Urolithin A activates Nrf2/ARE signalling in hepatic tissue.
That can increase antioxidant and detoxification programmes such as HO-1, NQO1, SOD, and glutathione-related pathways.
This matters in two different ways.
#### Hepatoprotection
In toxin and lipid-stress models, Urolithin A has protected hepatocytes against oxidative damage and inflammatory injury.
In an acetaminophen-induced liver-injury model, the protective effect depended on Nrf2.
When Nrf2 was knocked down, the benefit was lost.
In a high-lipid hepatocyte model, Urolithin A reduced inflammation and restored autophagy-related signalling through the same pathway.
That makes the hepatoprotective effect mechanistically convincing.
#### The established-HCC caution
Nrf2 is not a simple pathway in cancer.
In premalignant or chronic-injury contexts, Nrf2 activation may be protective and tumour-suppressive because it reduces mutagenic oxidative damage.
In established cancers, constitutive Nrf2 activity can sometimes support survival and treatment resistance.
That means Urolithin A's Nrf2 activation is probably easiest to interpret in prevention-linked or liver-protection contexts.
Its meaning inside established HCC needs more specific study.
### The gut-liver axis — alcohol-related liver disease and HCC risk
A large fraction of HCC develops from chronic liver injury long before a tumour appears.
That is why the gut-liver-axis work matters here.
In alcohol-related liver-disease models, Urolithin A acts at several levels.
#### Gut-barrier protection
Urolithin A helps preserve gut-barrier integrity in alcohol-exposed models.
That matters because increased gut permeability allows lipopolysaccharide and other bacterial products to enter portal circulation and drive inflammatory signalling in the liver.
#### Microbiome modulation
Urolithin A has also been linked to increased abundance of several beneficial microbial species associated with barrier health and anti-inflammatory signalling.
These include:
* *Bacteroides sartorii*
* *Parabacteroides distasonis*
* *Akkermansia muciniphila*
#### MUP1-mediated ER-stress reduction
A 2024 mechanistic study identified major urinary protein 1, or MUP1, as an important mediator through which Urolithin A reduces hepatic ER stress in alcohol-exposed mice.
This is one of the more specific gut-microbiota-liver-axis mechanisms in the literature.
Oral administration of Urolithin-A-enriched bacteria increased propionic-acid production and reduced ER stress through MUP1-related biology, partly mimicking direct Urolithin A treatment.
#### Hepatic steatosis reduction
Urolithin A also reduced alcohol-induced hepatic lipid accumulation in mouse models.
That matters because steatosis is one of the early states in the progression from chronic liver injury toward cirrhosis and, in some patients, HCC.
These findings are not direct anti-HCC treatment evidence.
They are still relevant to HCC because they act upstream on the disease ecology from which many liver cancers emerge.
### Sorafenib and combination context
Sorafenib remains an important systemic therapy in advanced HCC.
For Urolithin A itself, no published study has directly tested combination with sorafenib in HCC models.
That is a notable gap.
This matters because ABCG2-related resistance biology is relevant to sorafenib in some liver-cancer settings, and Urolithin A has documented ABCG2 effects in other cancers.
At the moment, that connection remains theoretical in HCC.
A 2025 analogue study on urolithin-derived compounds suggests this line of research is expanding, but it should not be treated as direct Urolithin A evidence.
### Portal-hypertension context
Very early conference-level data has suggested possible relevance of Urolithin A in portal-hypertension models.
Because portal hypertension is a major complication of cirrhosis, this is worth noting for tracking purposes.
It is still far too early to weight heavily.
### What remains unknown
Several gaps still define this page.
* no published direct in vivo HCC tumour-model data was identified in this research pass, which is an important limitation
* no sorafenib-combination data for Urolithin A itself
* no clear answer yet on whether Nrf2 activation helps or complicates interpretation in established HCC
* no epidemiologic or interventional human data on whether microbiome or gut-liver-axis effects reduce HCC incidence in high-risk populations
* no clinical trials in HCC patients
Those limits matter because they stop this page from being more clinically advanced than it is.
### Bottom line
The liver-cancer story for Urolithin A is biologically strong, but split across two different kinds of evidence.
The direct HCC cell-line data is promising and mechanistically rich.
The liver-protective and gut-liver-axis data is even stronger in some ways, but it mostly speaks to chronic liver injury, inflammation, and risk ecology rather than proven anti-tumour activity in established HCC.
That makes liver cancer an important page in this section.
It also makes it a page that needs more caution than the pancreatic, prostate, or colorectal evidence pages.
### References
Antiproliferative effect of Urolithin A on hepatocellular-carcinoma HepG2.2.15 cells by regulating the Lin28a/let-7a axis\
Urolithin A research overview and oncology applications\
In vitro antiproliferative and antioxidant effects of Urolithin A on HepG2 hepatic-carcinoma cells\
MUP1 mediates Urolithin A alleviation of chronic alcohol-related liver disease via the gut-microbiota-liver axis\
Urolithin A regulates the gut-liver axis to ameliorate alcohol-associated liver disease\
Urolithin A protects against acetaminophen-induced liver injury via activating Nrf2/ARE signalling\
Urolithin A inhibits inflammation and oxidative stress induced by high lipid in hepatocytes via activating Nrf2 pathway and autophagy\
Design, synthesis and biological evaluation of novel urolithin derivatives for anti-liver-cancer activity\
---
# Agent Instructions: Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/liver-cancer-hcc.md?ask=
```
The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.